Showing results (31-40 of 206) with videos related to

Sort By:
Pageof 21
Best Practice & Research. Clinical Haematology|February 11, 2014
Deletion 5q MDS: molecular and therapeutic implicationsRami S Komrokji, Eric Padron, Benjamin L Ebert, et al.
Current Opinion in Hematology|January 10, 2015
Current state of prognostication and risk stratification in myelodysplastic syndromesAmer M Zeidan, Steven D Gore, Eric Padron, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 1, 2022
Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS)Onyee Chan, Najla Al Ali, David Sallman, et al.
Virology|March 7, 2003
Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 4Nikola Kaludov, Eric Padron, Lakshmanan Govindasamy, et al.
European Journal of Haematology|August 18, 2021
Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomesAmy Song, Omar Altabbakh, David A Sallman, et al.
Cancer Genomics & Proteomics|March 3, 2018
Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center ExperienceMohammad Omar Hussaini, Abu-Sayeef Mirza, Rami Komrokji, et al.
Journal of Clinical Pathology|November 28, 2019
Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndromeIbraahim Badaat, Sabbir Mirza, Eric Padron, et al.
Journal of Virology|September 15, 2006
Structurally mapping the diverse phenotype of adeno-associated virus serotype 4Lakshmanan Govindasamy, Eric Padron, Robert McKenna, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic SyndromeMintallah Haider, Najla Al Ali, Eric Padron, et al.
Pageof 21